Non‐traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

Konstantino, Yuval; Wołk, Robert; Terra, Steven G.; Nguyen, Tu T.; Fryburg, David A.

doi:10.1080/17482940701474486

Cited by 11 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating markers of atherosclerosis are associated with increased vascular risk; one of the new biomarkers of atherosclerosis is Osteoprotegerin (OPG) [10]. Osteoprotegerin is a cytokine of the tumor necrosis factor (TNF) receptor superfamily and is classed as an osteoclastogenesis inhibiting factor [11].…”

Section: Introductionmentioning

confidence: 99%

Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

et al. 2017

View full text Add to dashboard Cite

BackgroundEarly vascular alteration, atherosclerosis and coronary artery disease have emerged as important cardiovascular complications among beta-thalassemia major (B-TM) patients. The aims of the current study were to assess the prevalence of premature atherosclerosis among our B-TM patients, and to investigate the diagnostic value of serum Osteoprotegerin assay as an early biomarker for atherosclerosis.MethodsThis cross-sectional study was conducted at Hematology unit - Pediatric Department, Zagazig University Children Hospital- Egypt in the period from March 2014 to March 2015. A total of 115 children were enrolled in the current study; as sixty-five (65) children with beta thalassemia major aged 5–18 years, on regular blood transfusion regimen represented the patient group. While fifty (50) healthy children, with comparable age and gender, were assigned as control group. All participants were subjected to history taking, thorough clinical examination and laboratory investigations including; complete blood count, liver and kidney function tests, C- reactive protein, lipid profile, serum ferritin and serum Osteoprotegerin (OPG) assay. Also, carotid artery intima media thickness (CAIMT) was performed by duplex ultrasound for patients and controls.ResultsOur B-TM patients were transfusion-dependent for as long as 8.5 ± 3.8 years with significantly higher serum ferritin levels (2490 ± 1579 ng/dl vs 83 ± 32 ng/dl, p = 0.001), C-reactive protein (5.7 ± 5.7 vs 0.9 ± 0.9), liver enzymes and bilirubin when compared to controls. Significantly higher serum triglyceride (128 ± 20 vs 101 ± 7 mg/dL, p = 0.009) and atherogenic index of plasma (0.45 ± 0.12 vs 0.22 ± 0.04, p = 0.001) were recorded in patients than comparisons. On the contrary, total serum cholesterol (116 ± 16 vs 143 ± 5, p < 0.001), low density lipoprotein-cholesterol (LDL-C) (44 ± 9 vs 73 ± 6, p < 0.001) and high density lipoprotein cholesterol (HDL-C) (39 ± 2 vs 61 ± 5, p < 0.001), were significantly lowered in patients versus normal peers. Carotid arteries intima media thickness (CAIMT) of both side were significantly increased for patients (Rt 0.62 ± 0.2 vs. 0.29 ± 0.07 mm, p = 0.001 & Lt 0.66 ± 0.17 vs 0.29 ± 0.05 mm, p = 0.001) when compared with healthy controls, and showed positive correlation with, serum triglyceride, atherogenic index of plasma, and serum Osteoprotegerin levels. ELISA assay of serum Osteoprotegerin (OPG) revealed significantly higher levels for thalassemia patients than matched healthy controls (427 ± 102 vs. 324 ± 126 pg/ml, p = 0.02). Of particular interest is the obvious positive correlation between OPG levels and CAIMT of both sides (Rt r 0.54, p = 0.001 &Lt r 0.479, p = 0.001) and also with serum triglycerides (r 0.374, p = 0.03).ConclusionsSubclinical atherosclerosis started prematurely in children with beta- thalassemia. Carotid artery intima media thickness represented a simple, accurate and non-invasivemodality for early detection ofatherosclerosis. It was correlated well with serum Osteoprotegerin; this finding highlighte...

show abstract

Section: Introductionmentioning

confidence: 99%

Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Konstantino et al (1) review the available nontraditional biomarkers that differentiate between stable and unstable coronary artery disease. We all need a simple blood test to tell us if a certain patient is likely to have an unstable coronary syndrome.…”

Section: Rafael Beyarmentioning

confidence: 99%

Biomarkers, imaging and interventions – going up hill

Beyar

2007

Acute Cardiac Care

View full text Add to dashboard Cite

“…However, for those who are in an intermediate-risk category, a recent meta-analysis concluded there is strong evidence that CRP has predictive value for cardiovascular events independent of other risk factors and that moderate evidence suggests that may improve risk stratification for those at intermediate risk 55. It has already been added to the European Society of Cardiology’s guidelines for risk stratification of patients with acute coronary syndrome 56. In the United States, the most recent American College of Cardiology/AHA guidelines for the assessment of asymptomatic adults listed measuring hsCRP as a Class IIa indication for men and women with LDL < 130 in order to decide whether or not to use a statin.…”

Section: Examples Of Current Biomarkersmentioning

confidence: 99%

Metabolic biomarkers for predicting cardiovascular disease

Montgomery¹,

Brown²

2013

VHRM

View full text Add to dashboard Cite

Cardiac and peripheral vascular biomarkers are increasingly becoming targets of both research and clinical practice. As of 2008, cardiovascular-related medical care accounts for greater than 20% of all the economic costs of illness in the United States. In the age of burgeoning financial pressures on the entire health care system, never has it been more important to try to understand who is at risk for cardiovascular disease in order to prevent new events. In this paper, we will discuss the cost of cardiovascular disease to society, clarify the definition of and need for biomarkers, offer an example of a current biomarker, namely high-sensitivity C-reactive protein, and finally examine the approval process for utilizing these in clinical practice.

show abstract

Non‐traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

Abstract: As ACS and stable CAD are characterized by different pathophysiological processes, it appears that the biomarkers that are associated with them are differently expressed in these two clinical conditions

Cited by 11 publications

References 48 publications

Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker

Biomarkers, imaging and interventions – going up hill

Metabolic biomarkers for predicting cardiovascular disease

Contact Info

Product

Resources

About